One Time. For a Lifetime.
Protection against stroke risk. Protection against oral anticoagulant (OAC) bleed risk. The WATCHMAN Implant is the one-time, minimally invasive procedure that protects your atrial fibrillation (AFib) patients for life.
Over 500,000 AFib patients have left blood thinners behind, replacing OACs with the WATCHMAN Left Atrial Appendage Closure (LAAC) Implant.1
Proven1
10 years
FDA approved
500,000+
patients treated
20+
years clinical experience
Safe2
99%
implant success rate*
0.5%
major adverse event rate†
Effective2
96.2%
of patients discontinued OACs at 45 days
Protect your patients: stroke risk reduction without the risks of OACs
Learn more about the WATCHMAN Implant and hear from cardiologists on this safe, OAC alternative for stroke risk reduction.
Learn more about WATCHMAN
Access resources
Access WATCHMAN resources in the referring HCP download center
Stay connected
Receive monthly updates about the WATCHMAN Implant
Rep visit
Connect with a local representative to learn more about the WATCHMAN Implant
Learn how the WATCHMAN Implant works
*Procedure success defined as successful delivery and release of a WATCHMAN FLX Device into the LAA.
†Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention.
References:
1. Represents all WATCHMAN models.
2. Kar, S., et al, Primary Outcome Evaluation of the Next Generation LAAC Device: Results from the PINNACLE FLX Trial, Circulation, 2021.
3. Joglar JA et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024